The gut microbiota and psychiatric illness Glenda MacQueen, MD, PhD; Michael Surette, PhD; Paul Moayyedi, MB, PhD
The global market for probiotics is projected to be worth al most $USD 100 billion by 2020, 1 reflecting growing acceptance that our intestinal microbiota can influence physiologic sys tems, including but not limited to the gut. Many lay publica tions enthusiastically tout the potential health benefits of an optimized microbiome -or conversely, the risks of dysbiosis. Depression, stress, anxiety and autism are all proposed to be at least partially sensitive to manipulation of the gut micro biome. Studies have suggested that a variety of conditions are influenced by the microbiome, including obesity, functional gastrointestinal (GI) disorders, chronic fatigue syndrome and inflammatory illnesses. All of these disorders also have an important central nervous system component. It is likely that a substantial portion of people who consume prebiotics or probiotics will do so with the aim of improving symptoms re lated to the brain.
How strong is the evidence on which decisions to take prebiotic or probiotic preparations are being made?
How strong is the evidence? In brief, not as strong as it needs to be. Animal studies consistently report that behaviour and the function of the nervous system are modulated by gut microbiota (see the reviews by Dinan and Cryan, 2 Foster 3 and Anglin and colleagues 4 ). Perturbing the gut microbiota in mice with antibiotics is associated with altered brainderived neurotrophic factor in the hippocampus and amygdala and an increase in mouse exploratory behaviour, considered a surrogate for decreased anxiety. 5 Chronic administration of Lactobacillus rhamnosus str. JB1 also increased exploratory be haviour, 6 and this effect was associated with brain regionspecific changes in the γaminobutyric acid (GABA) system and was dependent on vagal integrity. 6 Bifidobacterium longum NCC3001 normalized anxiety in mice with chemically induced lowgrade inflammation. 7 In contrast, other bacteria can induce anxietylike behaviour in rodents, and this is ef fect also appears to be mediated by the vagus nerve. 8, 9 Social disruption in rodent models is associated with reduced rich ness and diversity of the gut microbial community, along with shifts at the level of operational taxonomic units (OTUs; groups of microorganisms clustered by DNA sequence simi larity), suggesting a bidirectional component to brain-gutmicrobiota relations. 10, 11 Diet may also play a role. 12 Animal studies, therefore, provide strong support to the notion that altering the gut microbiota might result in altered behaviour.
Despite these persuasive animal data, relevant data from humans are extremely limited. Rather, the literature is mostly populated by reviews describing the potential of pre and probiotics to treat psychiatric conditions. A search of PubMed in January 2017 yielded almost 400 results from a search lim ited to reviews of "brain microbiome." Searching for "depres sion microbiome" alone yielded more than 100 reviews, and "anxiety microbiome" and "autism microbiome" yielded slightly fewer.
In contrast, running the same searches requesting clinical trials rather than reviews will yield only a few articles, and even fewer are actually clinical trials relevant to the condi tion. The human clinical data supporting a role of pre or pro biotics in other diseases, such as GI conditions, is stronger, but still limited. Systematic reviews suggest that probiotics are effective for symptoms of irritable bowel syndrome, for example, although a particular probiotic could not be recom mended because studies used various species and strains. 13 Although the paucity of data confirming the ability of the microbiome to enhance nervous system function is striking, there are a few recent studies that have yielded preliminary data supporting the notion that the intestinal microbiota can influence human behaviour. Steenbergen and colleagues 14 had 20 healthy participants consume either a multispecies probiotic or identical placebo for 4 weeks and found that the probiotic group had reduced cognitive reactivity to sad mood. These findings are consistent with those of a study in which healthy volunteers who took 1 of 2 prebiotics for 3 weeks had decreased attentional vigilance to negative ver sus positive information in a dotprobe task. 15 In that study, however, there were more measures (anxiety, perceived stress, memory) that did not change with either of the pre biotic products, making it hard to evaluate the significance of change on the dotprobe only. 15 A small study reported that women who consumed fermented milk product with pro biotics had changes in midbrain connectivity during an emo tional attention task compared with women who did not con sume the product with probiotics. 
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There have been a small number of case-control studies com paring gut microbiota of patients with psychiatric disorders to healthy controls. For example, Jiang and colleagues 17 noted that despite "profound interindividual variability," Bacteroidetes, Proteobacteria and Actinobacteria were increased in 46 people with active or treated major depressive disorder (MDD), whereas Firmicutes were reduced compared with 30 healthy controls. 17 Another recent study noted alterations in the phyla Firmicutes, Actinobacteria and Bacteroidetes in patients with MDD. 18 Whether alterations in the microbiome contributed to the onset of MDD or emerged as a result of the illness or phar macological treatment is unknown. One recent study found that there was no significant difference in species richness between depressed and non depressed participants, 19 although another study reported that depression was associated with decreased gut microbiota richness and diversity 20 and another reported lower Bifidobacterium counts in patients with MDD. 21 Fecal microbiota transfer from patients with MDD to microbiotadeficient animals can induce behavioural changes in the recipient animal that are considered analogues of de pression or anxiety. 18, 19 There are few reports of randomized controlled trials evalu ating the effect of probiotics in psychiatric patients. Tomasik and colleagues 22 randomized 58 people with schizophrenia to 14 weeks of adjunctive Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12 or placebo. Pro biotic treatment reduced levels of immunomodulatory proteins, but the clinical implications are unclear as there were no psychi atric outcomes measured in the trial. In another study, 40 people with major depression received either a capsule containing Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium bifidum or placebo for 8 weeks. 23 Those treated with the probiotic preparation had a significantly greater degree of improvement on the Beck Depression Inventory than those taking placebo.
There are clinical trials of probiotics for depression and/or anxiety in various stages of planning and running according to clinicaltrials.gov. However, many have small sample sizes and most have only 1 probiotic preparation. Given the large number of probiotics on the market containing single strains and com binations of organisms, the uncertainty as to which patient might benefit and what dose and what route to administer the probiotic, it is unlikely that these trials will provide clarity on the efficacy of probiotics in psychiatric disorders in the near future.
Furthermore, probiotics are just 1 approach to change the gut microbiome. There are even fewer data on diet, antibiot ics and fecal microbiota transplant therapy, some or all of which may have a role in modulating the gut microbiome to improve psychiatric illness.
What are the barriers to microbiome research in people with psychiatric illnesses?
There are substantial challenges to elucidating the role of the microbiome in human health and disease. A basic challenge is that there is no definition of what constitutes a healthy gut microbiota. 24 The term "dysbiosis" is widely used, but is a concept rather than a defined entity, and no researcher can confi dently state that an individual has an "unhealthy" gut micro biome. There is large variability among individuals in the composition of the microbiome, superimposed on variation in genetic and epigenetic susceptibilities to disease and dietary and environmental exposures. Thousands of micro bial species inhabit human populations, and there is no uni versal definition of a microbial "species" or OTUs across studies. The distributions of microbes across hosts vary greatly, providing challenges to statistical descriptions of human microbiome data. As noted above, there is little con sensus in the literature regarding what species are most likely to have therapeutic properties, and it may be the case that a balance of organisms, supported by a specific diet, pro vides the most benefit for any particular health condition. Trials of single or a few species may not represent an ade quate approach to manipulating an individual's microbiome.
Finally, describing alteration in the microbiota of people with psychiatric illness requires a multidisciplinary team, in cluding disciplines such as psychiatry, neurobiology, infor matics, microbiology, gastroenterology and epidemiology. Such a team would be difficult to assemble and coordinate.
Are there other ways to approach the study of the brain and microbiome?
Patients with GI disorders have higher rates of anxiety and depression than the general population 25 and those with other chronic diseases. 26 This applies to both patients with in flammatory bowel disease (IBD) 27 and those with irritable bowel syndrome (IBS). 28 The corollary is also true; patients with anxiety and depres sion have more GI symptoms than healthy controls. 29 A group recently reported that fecal microbiota signatures are similar be tween patients with depression and those with IBS in that they were less diverse than samples from controls and had similar abundances of alterations. 30 Although the gut-brain axis has been widely recognized, the nature of these interactions remains poorly understood. Studying psychiatric symptoms in people with and without GI disease may provide further insight into associations between diet, the microbiome, intestinal physiology and the neurobiology underlying some psychiatric illnesses.
A recent Canadian Institute for Health Research (CIHR)-funded Strategy for PatientOriented Research (SPOR) chronic disease network aims to explore this further. The Inflamma tion, Microbiome, and Alimentation: GastroIntestinal and Neuropsychiatric Effects (IMAGINE) network will assess diet, microbiome and a host of biological variables in 8000 partici pants with IBD and/or IBS as well as controls with no GI symptoms or disease. It is expected that approximately 20% of the cohort will have depression and/or anxiety, and this will be captured by including investigation of symptoms of depres sion and anxiety in a large cohort of patients with and without GI disease. The study is supported by a CIHR SPOR grant and is also funded by many partners and aims to follow partici pants for up to 4 years. A key hypothesis of the research pro gram is that alterations in the gut microbiome may also drive anxiety and depression associated with these GI disorders. A portion of the cohort will participate in treatment trials that will allow for testing of novel therapies for the treatment of IBD and IBS and the psychiatric disorders associated with these diseases. The research network supporting this program is multidisciplinary and engages gastroenterology, microbiol ogy, epidemiology, informatics psychiatry and psychology, encompassing both adult and pediatric disease. In the next few years, the IMAGINE network may be positioned to provide some of the most robust information available on the role of diet and the microbiome not only in individuals with GI dis ease, but also in those with depression and anxiety.
There is interest among both the research and lay com muni ties in understanding the effects of the microbiome on the brain. Patients and clinicians alike are keen to understand whether modifying the microbiome might provide a treat ment avenue for various neuropsychiatric conditions. Despite a relative abundance of reviews of the microbiome in human mental health and disease, actual data are sparse, and the widespread use of probiotics is not currently supported by randomized controlled trial data. Research programs that are comprehensive and bring together investigators from various disciplines may provide the best opportunity to move this ex citing but challenging field forward in the next decade.
